# Rheumatology News.

VOL. 15, No. 2

rheumatologynews.com

The Leading Independent Newspaper for the Rheumatologist

FEBRUARY 2016

## WHAT'S NEWS

The end of meaningful use will come this year, and it will "be replaced with something better," says CMS's Andy Slavitt. 11

#### Etanercept exposure

in pregnancy was associated with more than twofold higher odds of major structural defects, says Christina D. Chambers, Ph.D. 14

#### Pretreatment with sulfasalazine seems to prevent TNFi antibodies, but not as well as methotrexate, 18

The first U.S. clinical practice guidelines for Sjögren's are issued for systemic treatment, oral disease, and dry eyes. 24

Several state laws that permit privileged discussions between physicians and patients after medical errors are showing promise. 54

S TALKING

**Reminder** letters



## Step therapy and biologics: An easier road ahead?

Twelve states have passed legislation on step therapy varying in focus and scope.

BY JENNIE SMITH

aws recently passed or under consideration in state legislatures may offer some relief to physicians and patients dogged by the "step" or "fail-first" therapy protocols mandated by insurers, but until better clinical evidence is available to support treatment decisions and biosimilars reduce costs, clinicians must strategize to get patients through the step pathways as fast as possible.

Rheumatologists, gastroenterologists, and dermatologists all confront fail-first policies in their practices, particularly when prescribing the biologic agents that have been game changers in treating rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis, among other diseases.

In RA, for example, a patient might be required to fail a series of dis-



'By creating a step therapy pathway we're closing the window [of opportunity to treat these diseases] at least partially,' said rheumatologist Dr. Norman Gaylis.

ease-modifying antirheumatic drugs (DMARDs), including methotrexate, before starting a biologic. In Crohn's disease, patients might have to first

fail on steroids and immunosuppressants.

Most clinicians consider cost con-See Step therapy page 2

# Integrated care recommended for PsA

# Lowering hurdles for biologics | Rheumatology News

Step therapy from page 1

cerns fair as a basis for insurance decisions. But they can also have strong rationales for making exceptions. This may mean starting patients on a biologic early, particularly those they deem unlikely to respond to first- or second-line treatments - which may be cheaper but are not necessarily safer.

In egregious cases, a patient already stable on a biologic who has changed insurance plans may be forced to go backwards

in the treatment pathway, and fail first- and second-line therapies all over again before resuming - a process



unlikely to be cost-effective in the long term, and also rife with ethical concerns, say clinicians.

"Making a patient fail to get a less toxic drug sort of violates our 'do no harm' principle," Dr. Stephen B. Hanauer, medical director of the Digestive Health Center at Northwestern University, Chicago, said in an interview.

"I always say that if biologics cost a dollar, we'd be using them for everybody. If you take away the steroids and the

As insurers' first-choice biologic drug changes frequently, and varies from plan to plan, a patient who is stable on one agent might be asked to switch to another, a phenomenon known as nonmedical switching.

immunosuppressants, these are very safe drugs for IBD, far safer than steroids - but steroids are cheap," Dr. Hanauer said.

And with some debilitating disease presentations, such as severe Crohn's, "being told that we have to try conventional therapies and the patient has to fail them can mean putting the patient through progression of their disease, and suffering," Dr. David T. Rubin, codirector of the Digestive Diseases Center

at the University of Chicago, said in an interview. "We really struggle with this."

Dr. Joseph S. Eastern, a dermatologist practicing in Belleville, N.I., said his specialty faces similar challenges with step therapy. "Dermatologists as a group are pretty risk averse. When given the opportunity, we do an excellent job of prescribing conventional medications, ultraviolet therapy, and biologics in the most cost-effi-

> cient possible way," he said in an email. Yet "third-party payers tell us, for example,

that a pa-

DR. HANAUER

principle."

'Making a patient

fail to get a less

toxic drug sort

of violates our

"do no harm"

tient must fail methotrexate before we can use a biologic, when the whole advantage of biologic therapy for many of these patients is the avoidance of organotoxicity and other serious risks."

As a result, Dr. Eastern said, "I write a lot more vehement letters to payers about the biologics these days."

#### Choice vs. cost

Rheumatologists are among the clinicians most affected by fail-first and step therapy mandates, as the diseases they treat - particularly RA - are the most established indications for biologic therapies, and for which the largest number of these are approved.

Though Medicare and Medicaid allow physicians considerable leeway, private insurers often tightly circumscribe the timing and choice of biologics in RA. As insurers' first-choice biologic drug changes frequently, and varies from plan to plan, a patient who is stable on one agent might be asked to switch to another, a phenomenon known as nonmedical switching.

Insurers are seldom transparent about their reasons for establishing certain biologic drugs as their go-to agents, clinicians say, while making it difficult for physicians to prescribe others. There's a tremendous amount

Continued on page 4

Editor in Chief Mary Jo M. Dales Executive Editors Denise Fulton, Kathy Scarbeck Editor Jeff Evans

Senior Editors Therese Borden, Catherine Hackett, Gina L. Henderson, Susan Hite, Sally Koch Kubetin, Mark S. Lesney, Renée Matthews, Lora T. McGlade, Elizabeth Mechcatie, Catherine Cooper Nellist, Laura Nikolaides, Richard Pizzi, Terry Rudd, Mary Ellen Schneider Editorial Production Manager Carol Nicotera-Ward

Associate Editors Felicia Rosenblatt Black, Lucas Franki, Richard Franki, Gwendolyn B. Hall, Katie Lennon, Jane Locastro, Dan Watson

Reporters Birmingham: Sharon Worcester; Chicago:


Patrice Wendling: Denver: Bruce Jancin; Mid-Atlant Michele G. Sullivan; Midwest: Alicia Gallegos, Kan Oakes; Philadelphia: Mitchel L. Zoler; San Diego: Doug Brunk; Seattle: M. Alexander Otto; Washington: Deepak Chitnis, Whitney McKnight, Gregory Twachtman Multimedia Producer Nick Piegari

Contributing Writers Christine Kilgore, Mary Ann Moon, Jennie Smith

Meetings Database Manager Megan Evans Office Manager Marquia Chase

Editorial Offices 5635 Fishers Lane, Suite 6100, Rockville, MD 20852, 240-221-2400 rhnews@frontlinemedcom.com





Rheumatology News is an independent newspaper that provides the practicing specialist with timely and relevant news and commentary about clinical developments in the field and about the impact of health care policy on the specialty and the physician's practice.

The ideas and opinions expressed in Rheumatology News do not necessarily reflect those of the Publisher. Frontline Medical Communications Inc. will not assume responsibility for damages, loss, or claims of any kind arising from or related to the information contained in this publication, including any claims related to the products, drugs, or services mentioned herein.

POSTMASTER Send changes of address (with old mailing label) to Rheumatology News Subscription Service, 151 Fairchild Ave., Suite 2, Plainview, NY 11803-1709

Rheumatology News (ISSN 1541-9800) is published monthly by Frontline Medical Communications Inc., 7 Century Drive, Suite 302, Parsippany, NJ 07054-4609. Phone 973-206-3434, fax 973-206-9378. Subscription price is \$135.00 per year. Periodicals postage paid at Parsippany, NJ, and additional mailing offices

Copyright 2016, by Frontline Medical Communications Inc.

**Creative Director Louis Design Supervisor Eliz** Senior Designers Bonn Johnson, Tom C. Lore **Print Production Manaj Production Specialists** Draper

**Director**, Digital Publis Web Production Manag Web Production Specia James Owen, Benjam Doug Tu

E-Newsletter Content S

Digital Communication Senior Director, IT Lev Senior Systems Admin Systems Support Analy Adv. Services Manager Credit Supervisor Patri Convention Manager L



National Account Mana igallione@frontlineme **Classified Sales Repret** 973-290-8259, hgen Senior Director Classifi tlapella@frontlinemed Director, eBusiness Dev 973-206-8982, lschw Associate Director, eBu 201-400-7644, jnorti

Advertising Offices 7 NJ 07054-4609 973 Reprint/Eprint Contacts United States, its terri 877-652-5295, front Global: Content Ed Net

#### FRONTLINE MEDI

Chairman Stephen Sto **EVP Digital Business D** President/CEO Alan J. I President, Custom Solu Vice President, Finance Vice President, Operatio Vice President, Audienc Vice President, Custom Vice President, Custom Vice President, Human

**Carolyn Caccavelli** Vice President, Marketin Vice President, Sales P Vice President, Society I Corporate Director, Rese Director, eBusiness Dev In affiliation with Globa Vice President, Medical

Sylvia H. Reitman, MBA Vice President, Events

U

P

R

TI

S

Vi

G

EI

U

A

Br

N

H

## EDITORIAL ADVISORY BO

Roy D. Altman, M.D., University of California, Los Angeles

Dimitrios Boumpas, M.D., University of Crete, Heraklion, Greece

Christopher M. Burns, M.D., Dartmouth University, Lebanon, N.H.

Lisa G. Criscione-Schreiber, M.D., Duke University, Durham, N.C.

Daniel E. Furst, M.D., University of California, Los Angeles

#### Eric P. Gall, M.D., University of Arizona, Tucson

Norman B. Gaylis, M.D., Private Practice, Aventura, Fla.

Karen S. Kolba, M.D., Private Practice, Santa Maria, Calif.

Tore K. Kvien, M.D., University of Oslo

Thomas J.A. Lehman, M.D., The Hospital for Special Surgery, New York

Joan T. Merrill, M.D., Oklahoma Medical Research Foundation, Oklahoma City

### NEWS

#### Continued from page 2

of discounting going on that we are oblivious to as physicians. I've seen situations where drug A is the first one you have to use this month and the next month, drug C," said Dr. Norman Gaylis, a rheumatologist practicing in Aventura, Fla.

Attempting to start a patient on a nonpreferential biologic will generate paperwork and delays, Dr. Gaylis said, which can cost patients valuable time. "There's a window of opportunity to treat these diseases, and by creating a step therapy pathway we're closing the window at least partially."

"As an example, rituximab in most payer plans is not tiered as a first-line biologic treatment option despite the fact that there are frequent scenarios where the clinical and serological presentation of a patient would suggest it to be preferable as a first-line treat-

Model legislation for limiting step therapy has three basic objectives: 'We want a clear set of clinical guidelines, a quick review process, and overrides that allow for exceptions.'

ment choice over an anti-TNF [tumor necrosis factor]," Dr. Gaylis said.

"There is no room for clinical decision making based upon the unique presentation of each different patient when choosing the best treatment option," he said.

Rheumatologists often become overwhelmed with authorization pasaid, and for those who must move into the biologic realm, the vast majority will succeed on the first anti-TNF agent prescribed. And there is little science to establish that one TNF inhibitor is superior – only that patients can sometimes succeed with one and fail another.

"As far as which biologic to initiate,



'When I say I have tried this patient on maximal tolerable doses of all these DMARDs, they ought to believe me.'

DR. KOLBA

my personal opinion is I don't care, and I tell the patients that I don't mind if the insurer picks out of this category because I'm flipping a coin as well," she said.

Step mandates become objectionable, Dr. Kolba said, when they are purportedly based in science that doesn't exist, or when they seem to exist only to wear down the provider.

"With private insurance, not only do they have the drug of the year, they're going to make me battle for every single prescription. When I say I have tried this patient on maximal tolerable doses of all these DMARDs, they ought to believe me. Yet I get six-page forms back saying, 'Give me the start and stop dates of all the drugs you've used.""

#### States constrain fail first

For many specialists treating patients with biologics, some of these hurdles are already getting lowered.

of care, "somebody not being treated appropriately and down the line has organ damage or comorbidity because of incorrect treatment decisions due to step therapy is a higher burden."

Moreover, he said, "we'd seen protocols requiring five or more steps, and for each step you have to try it at least 90 days." For a patient with rheumatic or autoimmune disease, "getting through something like that can just be devastating."

In 2011, Connecticut, Mississippi, and Arkansas became the first states to pass legislation limiting some aspect of step therapy. Since then, nine additional states have passed legislation varying in focus and scope.

In Kentucky, for example, patients cannot be forced by their insurer to remain on an ineffective therapy for more than 30 days, and insurers must respond to physician requests for an override within 2 days. Mississippi allows physicians to override insurer decisions with proof of clinical evidence. In California, legislation passed last year aims to reduce bureaucracy and speed up response to physician requests for overrides.

Mr. Stone and Mr. Okazaki are working in a coalition with other dermatology, rheumatology, and GI groups to push bills in seven more states, including New York, North Carolina, and Ohio.

While all the bills differ in what they attempt to limit, the model legislation has three basic objectives, Mr. Okazaki said. "We want a clear set of clinical guidelines, a quick review process, and overrides that allow for exceptions in cases where patients

#### 'We're all looking for that magic

insurer in favor of a biologic drug is insufficient clinical evidence.

With IBD, Dr. Rubin said, "we need more longitudinal understanding" and better prognostic indicators "in order to justify spending the extra money or going to one of these therapies."

Dr. Hanauer said one of the lim-



'We need more longitudinal understanding' and better prognostic indicators to justify biologics.

DR: RUBIN

itations he faces in practice is insufficient clinical evidence for biologics early in the treatment pathway for IBD.

RA "is much more common than Crohn's disease is. In trials, it's much easier to recruit hundreds of patients [for an RA trial], while with Crohn's it's very hard to enroll more than a couple a year at most sites," he said. "And as you move earlier in the treatment pathway that becomes somewhat more difficult as well."

His solution for now, he said, is to follow established step pathways in an accelerated way, for "a rapid transition toward highly effective therapies" without having to face extensive pushback from insurers.

"The idea is to initiate immunosuppressants for any patients with sufficient disease activity to justify steroids," Dr. Hanauer said. "Their steroids are then tapered, and while on immunosuppressants, patients are in a perfect setup to get combination sentation of a patient would suggest it to be preferable as a first-line treat-

Model legislation for limiting step therapy has three basic objectives: 'We want a clear set of clinical guidelines, a quick review process, and overrides that allow for exceptions.'

ment choice over an anti-TNF [tumor necrosis factor]," Dr. Gaylis said.

"There is no room for clinical decision making based upon the unique presentation of each different patient when choosing the best treatment option," he said.

Rheumatologists often become overwhelmed with authorization paperwork, "and still in many instances end up with a denial of their request."

Dr. Karen Kolba, a rheumatologist in private practice in Santa Maria, Calif., said that she agreed in principle with the way step therapy protocols have been established, and that some of the frustration with step therapy amounts to a tendency among specialist clinicians to bristle at being told what to do.

"Physicians hate protocol," Dr. Kolba said. "But comparing one protocol to another is the only way we are going to make advances." It took the rheumatology community about 30 years to come to terms with the use of methotrexate in RA, she noted, and the stepped approach grew naturally from the treatment of methotrexate failures with biologic agents when these first emerged in the late 1990s.

A majority of RA patients started on a stepped approach using DMARDs will respond, Dr. Kolba category because I in hipping a coin as well," she said.

Step mandates become objectionable, Dr. Kolba said, when they are purportedly based in science that doesn't exist, or when they seem to exist only to wear down the provider.

"With private insurance, not only do they have the drug of the year, they're going to make me battle for every single prescription. When I say I have tried this patient on maximal tolerable doses of all these DMARDs, they ought to believe me. Yet I get six-page forms back saying, 'Give me the start and stop dates of all the drugs you've used.""

#### States constrain fail first

For many specialists treating patients with biologics, some of these hurdles are already getting lowered.

Concerns about physician choice, a lack of transparency in insurer decision making, and the ethics of forcing patients to fail have led advocacy groups to press hard in recent years for legislation limiting step therapy – with successes in a dozen states.

While the state legislation is not disease or drug specific, it has important implications for clinicians treating with biologics. "Step therapy in its genesis was a good idea – it's OK to try to reduce costs in the health care system," said Patrick Stone, state government relations manager at the National Psoriasis Foundation in Annapolis, Md., a group that works extensively on step therapy issues. "But when these protocols were first crafted, medications like biologics weren't in use."

Jeff Okazaki, associate director of the Coalition of State Rheumatology Organizations, a group based in Schaumberg, Ill., said lawmakers are starting to accept that in terms of cost override within 2 days. Mississippi allows physicians to override insurer decisions with proof of clinical evidence. In California, legislation passed last year aims to reduce bureaucracy and speed up response to physician requests for overrides.

Mr. Stone and Mr. Okazaki are working in a coalition with other dermatology, rheumatology, and GI groups to push bills in seven more states, including New York, North Carolina, and Ohio.

While all the bills differ in what they attempt to limit, the model legislation has three basic objectives, Mr. Okazaki said. "We want a clear set of clinical guidelines, a quick review process, and overrides that allow for exceptions in cases where patients

"We're all looking for that magic biologic marker to tell me which drug to use, because God knows if I had a blood test that said "this is the drug," I would go to the mat with the insurer.'

shouldn't have to go through step therapy."

#### Clinical strategies and research gaps

New legislation undoubtedly will help providers and patients get access to their choice of treatment agents. But so long as biologics are expensive – and it will be a while before the first biosimilar drugs, which will have efficacy and safety similar to their reference biologics, reduce prices in any meaningful way – step therapy will likely remain the norm.

One of the key difficulties providers face when pushing back on an IBD.

RA "is much more common than Crohn's disease is. In trials, it's much easier to recruit hundreds of patients [for an RA trial], while with Crohn's it's very hard to enroll more than a couple a year at most sites," he said. "And as you move earlier in the treatment pathway that becomes somewhat more difficult as well."

His solution for now, he said, is to follow established step pathways in an accelerated way, for "a rapid transition toward highly effective therapies" without having to face extensive pushback from insurers.

"The idea is to initiate immunosuppressants for any patients with sufficient disease activity to justify steroids," Dr. Hanauer said. "Their steroids are then tapered, and while on immunosuppressants, patients are in a perfect setup to get combination therapy with an immunosuppressive and a biologic – and that's a 2- to 3-month transition, not 2-3 years."

Dr. Kolba said that despite the wide array of options for treating RA, the specialty suffers from a dearth of understanding as to why some patients fail drugs while others succeed, even within the same drug class.

Rheumatologists' prescribing choices would be highly influenced by better biomarkers, were they to become available, she said. And they'd have far better arguments when confronted with payer pushback.

"We're all looking for that magic biologic marker to tell me which drug to use," Dr. Kolba said, "because God knows if I had a blood test that said 'this is the drug,' I would go to the mat with the insurer."

rhnews@frontlinemedcom.com